Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $7.84 and traded as low as $7.46. Atara Biotherapeutics shares last traded at $7.70, with a volume of 17,041 shares traded.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on ATRA. Wall Street Zen raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings raised Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.50.
Get Our Latest Analysis on ATRA
Atara Biotherapeutics Stock Performance
The stock has a 50-day moving average price of $8.94 and a two-hundred day moving average price of $7.84. The stock has a market capitalization of $78.46 million, a PE ratio of -7.62 and a beta of 0.28.
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last released its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $1.22 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, equities analysts predict that Atara Biotherapeutics, Inc. will post -0.22 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Anhco Nguyen sold 5,062 shares of Atara Biotherapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $8.08, for a total transaction of $40,900.96. Following the transaction, the chief executive officer owned 132,775 shares in the company, valued at approximately $1,072,822. The trade was a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian N. Cherry bought 104,166 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $9.60 per share, with a total value of $999,993.60. Following the acquisition, the director directly owned 166,486 shares in the company, valued at $1,598,265.60. This trade represents a 167.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 41.20% of the company’s stock.
Institutional Investors Weigh In On Atara Biotherapeutics
An institutional investor recently bought a new stake in Atara Biotherapeutics stock. Empowered Funds LLC bought a new position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,760 shares of the biotechnology company’s stock, valued at approximately $117,000. Empowered Funds LLC owned about 0.14% of Atara Biotherapeutics at the end of the most recent quarter. 70.90% of the stock is owned by institutional investors and hedge funds.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer and other serious diseases. Founded in 2012 and based in Thousand Oaks, California, the company’s approach uses immune cells from donors rather than cells collected from each individual patient. Its lead therapy, tabelecleucel, is an Epstein-Barr virus (EBV)-specific T-cell treatment for EBV-positive post-transplant lymphoproliferative disease, a rare complication that can occur after an organ or stem-cell transplant.
Recommended Stories
- Five stocks we like better than Atara Biotherapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
